Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Quantbot Technologies LP

Quantbot Technologies LP grew its stake in Becton, Dickinson and Company (NYSE:BDX) by 86.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 30,143 shares of the medical instruments supplier’s stock after buying an additional 13,992 shares during the quarter. Quantbot Technologies LP’s holdings in Becton, Dickinson and Company were worth $7,045,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $27,000. OLD Point Trust & Financial Services N A purchased a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $29,000. Scarborough Advisors LLC acquired a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $32,000. Rise Advisors LLC purchased a new position in shares of Becton, Dickinson and Company in the first quarter valued at approximately $38,000. Finally, ICA Group Wealth Management LLC acquired a new stake in shares of Becton, Dickinson and Company in the fourth quarter worth approximately $42,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Down 0.6 %

Shares of NYSE BDX opened at $234.18 on Monday. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The business’s 50 day moving average is $234.71 and its two-hundred day moving average is $235.61. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $269.52. The firm has a market cap of $67.68 billion, a price-to-earnings ratio of 51.58, a PEG ratio of 1.91 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.19. The firm had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.96 EPS. Research analysts predict that Becton, Dickinson and Company will post 13.1 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.62%. The ex-dividend date is Monday, September 9th. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Analyst Upgrades and Downgrades

Several research firms recently commented on BDX. Evercore ISI reduced their price objective on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Raymond James decreased their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. The Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price on the stock. Finally, Stifel Nicolaus increased their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $279.50.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.